FF304 翌日披露報表 (股份發行人 ── 已發行股本變動及/或股份購回) 表格類別： 股票 狀態： 新提交 公司名稱： 上海昊海生物科技股份有限公司（於中華人民共和國註冊成立的股份有限公司） 呈交日期： 2023年11月6日 | 第一章節 | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 | H | | 於香港聯交所上市(註11) | 是 | | | 證券代號 (如於香港聯交所上市) | 06826 | 說明 | H 股 | | | | | | 發行股份 | (註6及7) | 股份數目 | | 已發行股份佔 有關股份發行前的 現有已發行股份數目 百分比 (註4、6及7) | 每股發行價 (註1及7) | 上一個營業日 的每股收市價 (註5) | 發行價較市值的折讓/ 溢價幅度(百分比) (註7) | | 於下列日期開始時的結存(註2) | 2023年11月3日 | | 32,895,100 | | | | | | 1). 購回股份(或其他證券)但沒有註銷 | | | 20,700 ...

Financial Performance - Basic earnings per share for the third quarter were CNY 0.71, a 36.54% increase compared to the same period last year[5] - The company's net profit attributable to shareholders for the year-to-date period increased significantly, leading to a basic earnings per share of CNY 1.91, up from CNY 0.93 in the previous year[17] - The total comprehensive income for the period was CNY 323,974,453.15, compared to CNY 113,155,858.77 in the same period last year[17] - The net profit attributable to shareholders for Q3 2023 was ¥121,568,232.09, reflecting a growth of 34.00% year-over-year[21] - The net profit attributable to shareholders for the year-to-date period was ¥326,802,993.69, which is a significant increase of 102.04% year-over-year[21] - The company reported a net profit of CNY 326,967,441.02 for the first three quarters of 2023, compared to CNY 166,259,426.07 in the same period of 2022, reflecting an increase of about 96.66%[41] Revenue and Sales Growth - The company's operating revenue for Q3 2023 was ¥668,887,006.49, representing an increase of 8.80% compared to the same period last year[21] - For the year-to-date period, the operating revenue reached ¥1,981,789,458.11, marking a 25.23% increase compared to the same period last year[21] - The company experienced a significant increase in sales of its medical beauty hyaluronic acid products, with revenue growth exceeding 50% compared to the previous year[25] - The company’s sales revenue for the first three quarters of 2023 was CNY 2,153,855,868.18, compared to CNY 1,688,544,097.45 in the same period of 2022, reflecting an increase of approximately 27.5%[42] Research and Development - The total R&D investment amounted to CNY 52,763,351.61, representing 7.89% of operating revenue, an increase of 0.65 percentage points year-on-year[5] - The proportion of R&D investment to operating revenue has shown a consistent upward trend, indicating a strong commitment to innovation[5] - Research and development expenses for the first three quarters of 2023 were CNY 154,154,668.27, compared to CNY 121,221,455.33 in the same period of 2022, marking an increase of about 27.2%[41] Cash Flow and Assets - The net cash flow from operating activities increased by 116.37% year-to-date, primarily due to significant growth in operating revenue[9] - The net cash flow from operating activities for the year-to-date period was ¥391,564,343.48, showing a growth of 116.37% compared to the previous year[21] - Cash and cash equivalents at the end of the reporting period were CNY 406,363,089.01, down from CNY 682,889,664.04 at the end of 2022, a decrease of approximately 40.43%[39] - The cash inflow from investment activities totaled CNY 1,089,423,627.13 for the current period, compared to CNY 990,170,755.22 in the previous period, indicating an increase of about 10.03%[37] Equity and Liabilities - Total assets at the end of the reporting period were CNY 7,089,426,530.74, reflecting a 2.86% increase from the end of the previous year[5] - The company reported a total equity attributable to shareholders of CNY 5,704,966,947.12, a 3.45% increase from the previous year[5] - The total liabilities as of September 30, 2023, were ¥1,011,068,562.86, compared to ¥990,013,737.98 at the end of the previous period[33] - The company’s total liabilities increased to CNY 3,715,795,672.92 as of September 30, 2023, from CNY 3,532,115,166.92 at the end of 2022, representing a growth of approximately 5.18%[39]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容而產生或因依 賴該等內容而引致的任何損失承擔任何責任。 Shanghai Haohai Biological Technology Co., Ltd.* 上海昊海生物科技股份有限公司 （於中華人民共和國註冊成立的股份有限公司） （股份代號：6826） 2023年第三季度報告 本公告乃上海昊海生物科技股份有限公司（「本公司」，連同其附屬公司統稱「本集 團」）根據香港聯合交易所有限公司證券上市規則第13.09(2)及13.10B條以及香港 法例第571章證券及期貨條例第XIVA部刊發，旨在向本公司股東及公眾人士提供 本公司最新的財務資料。本公告亦同時在上海證券交易所網站發佈。 茲載列本集團截至2023年9月30日止三個月及九個月未經審計業績（「第三季度報 告」）。第三季度報告所載財務數據乃根據中國企業會計準則編製，且未經審計。 提請本公司潛在投資者及股東注意潛在投資風險。 第三季度報告以中英文版本編製。有任何歧義，概以第三季度報告中文版本為準。 承董事會命 上海 ...

Financial Performance - The company recorded a revenue of approximately RMB 1,305.71 million for the six months ended June 30, 2023, representing an increase of approximately RMB 349.44 million or 36.54% compared to the same period in 2022[9]. - The net profit attributable to equity holders of the company was approximately RMB 205.24 million, a significant increase of approximately RMB 134.21 million or 188.94% compared to the same period in 2022[9][14]. - The company’s basic earnings per share for the reporting period were RMB 1.20, compared to RMB 0.41 in the same period last year[9]. - The gross profit for the same period is RMB 926.42 million, up from RMB 666.78 million, reflecting a gross margin improvement[77]. - The company reported a net profit of RMB 205,235,000 for the six months ended June 30, 2023, compared to RMB 114,764,000 for the same period in 2022, representing an increase of approximately 78.8%[86]. - The company achieved a profit attributable to ordinary equity holders of approximately RMB 205.24 million, a significant increase of about RMB 134.21 million or 188.94% compared to RMB 71.03 million in the same period last year[57]. Revenue Breakdown - The revenue breakdown by product line for the first half of 2023 showed significant growth in all categories, with ophthalmology products contributing RMB 479.15 million (36.70% of total revenue) and medical aesthetics products contributing RMB 483.50 million (37.03%)[10]. - Revenue from ophthalmic products was RMB 479,149 thousand, up 35.4% from RMB 354,161 thousand year-on-year[104]. - Revenue from medical beauty and wound care products increased to RMB 483,499 thousand, representing a 47.8% growth compared to RMB 327,057 thousand in the previous year[104]. - The artificial lens segment reported revenue of approximately RMB 202.92 million, an increase of RMB 74.91 million, or 58.51%, driven by a rapid recovery in cataract surgeries nationwide[17]. - The company’s hyaluronic acid products achieved revenue of approximately RMB 255.24 million, an increase of RMB 136.44 million compared to the same period last year, representing a growth rate of 114.85%[35]. Research and Development - Research and development expenses amounted to approximately RMB 101.39 million, an increase of approximately RMB 24.68 million or 32.17% year-on-year, accounting for 7.77% of total revenue[9][11]. - Clinical trials for multiple key R&D projects, including various types of intraocular lenses, are progressing smoothly, with one product already approved for registration in June 2023[11]. - The company is focusing on expanding its ophthalmology and medical aesthetics product lines, with several key research and development projects progressing smoothly[11]. - The company plans to focus on the development of new products in the ophthalmology sector, including various types of intraocular lenses and myopia control products, in the second half of 2023[46]. Market Position and Strategy - The company is actively developing high-end artificial lens products, including astigmatism correction and multifocal lenses, supported by national research and development plans[21]. - The company has established a complete industrial chain layout for artificial lenses, integrating upstream raw material production and downstream sales channels[21]. - The market share of the company's ophthalmic viscoelastic products decreased from 50.83% in 2021 to 44.52% in 2022, but it remains the largest in China for 16 consecutive years[15]. - The company has exclusive distribution rights for high-end orthokeratology lenses in mainland China, enhancing its market share and influence in this segment[25]. Assets and Liabilities - The total assets of the company at the end of the reporting period were approximately RMB 7,254.17 million, with net assets attributable to equity holders amounting to RMB 5,709.62 million, reflecting increases of approximately RMB 361.77 million and RMB 195.01 million, respectively, compared to the end of 2022[14]. - The total current assets as of June 30, 2023, were approximately RMB 3,878.57 million, an increase of about RMB 346.45 million or 9.81% from the end of 2022[59]. - The total liabilities of the group as of June 30, 2023, are approximately RMB 1,163.60 million, with a debt-to-asset ratio of 16.04%, an increase of 1.68 percentage points from 14.36% as of December 31, 2022[67]. - The company’s total liabilities to total assets ratio increased, indicating a higher leverage position compared to the previous year[83]. Employee and Compensation - As of June 30, 2023, the total number of employees in the group is 2,123, with 810 in production, 341 in R&D, 646 in sales and marketing, 88 in finance, and 238 in administration[62]. - The total employee compensation for the reporting period is approximately RMB 315.53 million[62]. Corporate Governance - The company has complied with all applicable code provisions of the Corporate Governance Code during the reporting period[182]. - The company continues to review and enhance its corporate governance practices to ensure compliance with the Corporate Governance Code[182]. - The interim financial statements were approved by the board on August 17, 2023, and published on the Hong Kong Stock Exchange website[157]. Dividend Policy - The company did not recommend the payment of an interim dividend for the six months ended June 30, 2023[9]. - The proposed final dividend for the year ended December 31, 2022, is RMB 0.40 per share, while no interim dividend is recommended for the six months ended June 30, 2023[116].

证券代码：688366 证券简称：昊海生科 公告编号：2023-039 上海昊海生物科技股份有限公司 股东减持股份期限届满暨减持结果公告 本公司董事会、全体董事及相关股东保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律 责任。 1 6,151,186 股，占公司目前总股本 171,287,974 股的 3.5911%。本次减持计划实施 完毕，现将具体情况公告如下。 注：持股比例系占本次减持计划披露时公司总股本 171,271,000 股的比例。 上述减持主体无一致行动人。 2 重要内容提示： 股东持股的基本情况 上海昊海生物科技股份有限公司（以下简称"公司"）股东楼国梁先生于本 次减持计划实施前持有公司无限售条件流通股股份为 7,125,075 股，占减持计划 披露时公司总股本 171,271,000 股的 4.1601%。 上述股份来源于公司首次公开发行前，已于 2020 年 10 月 30 日解除限售并 上市流通。 减持计划的实施结果情况 公司于 2023 年 2 月 18 日披露了《上海昊海生物科技股份有限公司股东减持 股份计划公告》（公告编号： ...

证券代码：688366 证券简称：昊海生科 公告编号：2023-038 上海昊海生物科技股份有限公司 关于以集中竞价交易方式回购公司A股股份方案的公告 1、 拟回购股份的用途：回购的股份将在未来适宜时机全部用于员工持股计 划及/或股权激励，并在股份回购实施结果暨股份变动公告后三年内予以转让， 若未能在前述期间内转让完毕，则将依法履行相关程序予以注销并减少注册资本； 2、 回购方式：上海证券交易所交易系统集中竞价交易； 3、 回购期限：自股东大会审议通过本次回购方案之日起 12 个月内； 4、 回购价格：不超过人民币 130.00 元/股（含）； 5、 拟回购股份的资金总额：不低于人民币 10,000.00 万元（含），不超过人 民币 20,000.00 万元（含）。 ● 本次回购资金来源为公司自有资金。 ● 相关股东是否存在减持计划： 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： ● 上海昊海生物科技股份有限公司（以下简称"公司"）本次以集中竞价 交易方式拟回购部分公司已发行的人民币普通股（A 股）股票， ...

Financial Performance - The company's total assets reached RMB 7,254.17 million, and net assets attributable to shareholders increased by RMB 1,949.07 million compared to the end of 2022[6]. - The company reported a 35.66% increase in overall revenue, attributed to the normalization of operations after previous disruptions[15]. - The company's operating revenue for the reporting period reached approximately RMB 1.31 billion, representing a year-on-year increase of 35.66%[49]. - The company reported a revenue of CNY 1.5 billion for the first half of 2023, representing a year-over-year increase of 25%[160]. - The net profit attributable to shareholders of the listed company increased by 188.94% year-on-year, amounting to approximately CNY 205.23 million[169]. - The basic earnings per share (EPS) rose to CNY 1.20, reflecting a 192.68% increase compared to the previous year[164]. - The gross margin for the first half of 2023 improved to 45%, up from 40% in the previous year[160]. - The net cash flow from operating activities increased by 147.44% year-on-year, primarily driven by significant growth in operating revenue[38]. - The company's R&D investment accounted for 7.72% of operating revenue, slightly down by 0.21 percentage points from the previous year[164]. Revenue Breakdown - Revenue from the myopia prevention and refractive correction product line was RMB 206.06 million, a year-on-year increase of 16.36%[7]. - Revenue from optical materials business was RMB 110.38 million, up 42.21% year-on-year, benefiting from the recovery of global operations[7]. - Revenue from cataract products reached RMB 259.62 million, a significant increase of 55.20% year-on-year, driven by the rapid recovery of cataract surgeries[18]. - Revenue from medical beauty and wound care products was RMB 484.87 million, an increase of 47.49% year-on-year[28]. - The revenue from the orthopedic product line was RMB 231.83 million, a year-on-year increase of 29.74%[42]. - The revenue from anti-adhesion and hemostatic products was RMB 90.74 million, reflecting a year-on-year growth of 7.87%[43]. - The company's hyaluronic acid products achieved sales revenue of RMB 255.96 million, an increase of RMB 136.55 million compared to the same period last year, representing a growth rate of 114.35%[56]. - The third-generation hyaluronic acid product "Haimi" generated sales revenue exceeding RMB 115 million, with a year-on-year growth of 377.37%[58]. - The medical chitosan product for intra-articular injection saw revenue growth of 60.77%, with sales reaching RMB 80.82 million compared to RMB 50.27 million in the previous year[60]. Market Position and Share - The company’s market share in the anti-adhesion materials segment was 29.90%, making it the largest supplier in China[43]. - The company holds a 46.54% market share in the domestic orthopedic joint injection product market, maintaining its position as the leading manufacturer for nine consecutive years[61]. - The market for external epidermal growth factor products in China was approximately CNY 823 million in 2022, projected to grow to CNY 1.813 billion by 2027, with a compound annual growth rate of about 17.11%[196]. - The company is the largest domestic producer of surgical adhesion prevention agents and a major producer of medical collagen sponge, enhancing surgical safety and recovery[185]. - The company is the largest domestic producer of orthopedic joint cavity viscoelastic supplements, addressing common degenerative joint diseases in the elderly[190]. Research and Development - The company plans to focus on the clinical trials of several innovative products, including hydrophobic aspheric toric intraocular lenses and the second-generation PRL products in the second half of 2023[32]. - Research and development expenses increased by 32.17% to RMB 101.39 million, indicating a focus on innovation[49]. - The company is investing CNY 500 million in R&D for new biopharmaceutical technologies over the next two years[160]. - The group has increased R&D investment during the reporting period to develop new technologies and products, as well as to transform core technological achievements[199]. - The company is advancing clinical trials for a new biological gel product aimed at treating retinal detachment[173]. Environmental Commitment - The environmental pollution discharge from the company and its subsidiary, Likangrui, did not exceed the standard limits during the reporting period[76]. - The company has established a water reuse system to enhance water resource utilization efficiency[95]. - The company has obtained ISO 14001 environmental management system certification, demonstrating its commitment to sustainable development[108]. - The company has implemented continuous online monitoring of major pollutants in wastewater and waste gas, ensuring compliance with environmental regulations[107]. - The company has set carbon emission reduction targets and is actively seeking ways to optimize resource usage through facility upgrades and process improvements[95]. Corporate Governance and Compliance - The company held its annual general meeting on June 12, 2023, where several key resolutions were passed, including the approval of the 2022 financial statements[80]. - The company’s board of directors was authorized to repurchase H shares during the first A-share and H-share shareholder meetings held on June 12, 2023[80]. - The semi-annual report has not been audited, ensuring transparency in financial reporting[140]. - The management has highlighted the importance of risk factors in the report, advising investors to be cautious[136]. - There are no significant risks or violations related to non-operational fund occupation by controlling shareholders or related parties[139].

Financial Performance - The company recorded a revenue of approximately RMB 1,305.71 million for the six months ended June 30, 2023, representing an increase of approximately RMB 349.44 million or 36.54% compared to the same period in 2022[1]. - Profit attributable to equity holders of the company was approximately RMB 205.24 million, a significant increase of approximately RMB 134.21 million or 188.94% compared to RMB 71.03 million in the same period last year[1]. - Basic earnings per share for the period were RMB 1.20, compared to RMB 0.41 in the same period of 2022[3]. - Gross profit for the period was RMB 926.42 million, compared to RMB 666.78 million in the same period of 2022, reflecting a strong growth in profitability[2]. - The overall gross profit margin increased to 70.95% in the reporting period, up from 69.73% in the previous year, driven by the rising revenue from hyaluronic acid products[37]. Research and Development - Research and development expenses amounted to approximately RMB 101.39 million, an increase of approximately RMB 24.68 million or 32.17% year-on-year, accounting for 7.77% of total revenue[1]. - The company is engaged in research and development of biopharmaceuticals and related services, indicating ongoing innovation efforts[7]. - R&D expenses for the period were RMB 101,391 thousand, representing a 32.2% increase compared to RMB 76,711 thousand in the same period last year[19]. - The company is focusing on expanding its ophthalmic and medical aesthetic product lines, with several key R&D projects progressing smoothly, including the registration of innovative products[38]. Assets and Liabilities - The total value of non-current assets as of June 30, 2023, was RMB 3,375.60 million, slightly up from RMB 3,360.28 million at the end of 2022[4]. - Current assets totaled RMB 3,878.57 million, an increase from RMB 3,532.12 million at the end of 2022[4]. - The company reported a net asset value of RMB 6,090.57 million as of June 30, 2023, compared to RMB 5,902.38 million at the end of 2022[5]. - Total current liabilities were approximately RMB 657.79 million, an increase of about RMB 146.51 million or 28.66% from the end of 2022, primarily due to increased dividend payables[66]. - The company's total liabilities were approximately RMB 1,163.60 million, with a debt-to-asset ratio of 16.04%, up from 14.36% at the end of 2022[71]. Market and Revenue Breakdown - Revenue from mainland China was RMB 1,059,733,000, up 34.5% from RMB 787,631,000 year-on-year[13]. - Revenue from ophthalmic products was RMB 479,149 thousand, up 35.4% from RMB 354,161 thousand year-on-year[15]. - Revenue from medical beauty and wound care products increased to RMB 483,499 thousand, a 47.8% rise from RMB 327,057 thousand in the previous year[15]. - The company continues to expand its market presence, with revenue contributions from Europe, the United States, and other regions increasing significantly[13]. Shareholder Actions - The company did not recommend the payment of an interim dividend for the six months ended June 30, 2023[1]. - The company repurchased 575,900 H shares during the reporting period, which were subsequently canceled on June 16, 2023[7]. - The company issued 592,874 A shares under the 2021 A-share restricted stock incentive plan during the reporting period[7]. Future Outlook and Strategy - The company plans to focus on four rapidly developing treatment areas: ophthalmology, medical aesthetics, wound care, and orthopedics, emphasizing research and innovation[57]. - In the second half of 2023, the company aims to enhance integration of acquired businesses to maximize operational efficiency and core competitiveness[58]. - The company will continue to advance the clinical trials of key innovative products, including various types of intraocular lenses and myopia control products[58]. - The company is set to strengthen its brand presence in the medical aesthetics sector, particularly for its high-end hyaluronic acid products[59].

证券代码：688366 证券简称：昊海生科 公告编号：2023-034 上海昊海生物科技股份有限公司 2023 年半年度募集资金存放与实际使用情况的专项报告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、 募集资金基本情况 （一）实际募集资金金额、资金到账时间 上海昊海生物科技股份有限公司（以下简称"公司"或"本公司"）经中国证 券监督管理委员会证监许可[2019]1793号文同意，由主承销商瑞银证券有限责任公 司采用向战略投资者定向配售、网下向符合条件的投资者询价配售、网上向持有上 海市场非限售Ａ股股份和非限售存托凭证市值的社会公众投资者定价发行相结合 的方式进行，向社会公开发行了人民币普通股（A股）股票17,800,000股，发行价为 每股人民币89.23元，共计募集资金总额为人民币1,588,294,000.00元，扣除券商承 销佣金及保荐费人民币46,450,107.55元和增值税2,787,006.45元后，主承销商瑞银证 券有限责任公司于2019年10月25日汇入公司募集资金监管账户中国光大银行股份 有限 ...

Financial Performance - The net profit attributable to shareholders for the first quarter was ¥9,613,418.44 after accounting for taxes and minority interests[6]. - The net profit attributable to shareholders of the listed company increased due to significant growth in operating income[33]. - Net profit attributable to shareholders of the listed company was ¥81,177,581.15, up 33.21% from ¥60,941,331.70 in the same period last year[41]. - The company reported a total profit of ¥112,095,668.59 for Q1 2023, compared to ¥69,806,178.33 in Q1 2022[48]. - Basic and diluted earnings per share both stood at ¥0.47, reflecting an increase driven by the growth in net profit attributable to shareholders[18][33]. - Basic earnings per share for Q1 2023 were ¥0.47, compared to ¥0.35 in the same period last year[41]. Revenue and Sales - Total operating revenue for Q1 2023 reached ¥611,252,893.65, representing a 29.06% increase compared to ¥473,617,820.88 in Q1 2022[48]. - The company experienced a significant increase in sales revenue from hyaluronic acid products due to the rapid recovery of the domestic medical beauty industry[33]. Assets and Liabilities - The total assets of the company as of March 31, 2023, amounted to ¥6,984,036,145.39, an increase from ¥6,892,398,253.88 as of December 31, 2022[12]. - The company's total assets increased by 1.33% to ¥6,984,036,145.39 compared to the end of the previous year[18]. - The total current assets increased to ¥3,660,348,521.72 from ¥3,532,115,166.92 year-over-year[12]. - The total liabilities increased to ¥1,087,042,005.92, up from ¥990,013,737.98, indicating a rise in financial obligations[18]. - The company's equity attributable to shareholders was ¥5,514,492,058.38, showing a slight decrease from the previous year's figure[18]. Cash Flow - Operating cash inflow from sales of goods and services reached ¥633,139,253.73, up from ¥511,144,187.98 in the same period last year[29]. - Net cash flow from operating activities was ¥79,930,962.49, a significant increase of 1,687.78% compared to ¥4,470,962.15 in Q1 2022[43]. - Cash flow from operating activities saw a substantial increase, attributed to the rise in operating income and previous inventory buildup[33]. - The company recorded a net cash flow from investing activities of ¥156,184,009.96, contrasting with a negative cash flow of -¥174,414,144.19 in Q1 2022[43]. Research and Development - Research and development expenses totaled ¥53,624,174.05, accounting for 8.77% of operating income, a decrease of 0.84 percentage points[18]. - Research and development expenses increased to ¥53,624,174.05 from ¥45,520,090.97, reflecting a focus on innovation[48]. Inventory and Receivables - The inventory value as of March 31, 2023, was ¥526,744,476.16, up from ¥485,238,796.88 in the previous year[12]. - The company’s accounts receivable increased to ¥415,730,029.31 from ¥381,526,389.55 year-over-year[12]. Investments - The company’s long-term equity investments decreased to ¥2,858,785.76 from ¥3,028,473.17 year-over-year[12]. - The company achieved an investment income of ¥517,071.28, down from ¥2,313,643.50 in Q1 2022[48]. Shareholder Information - The company reported a total of 8,369 ordinary shareholders at the end of the reporting period[34].